In APL therapy topoisomerase II inhibitors (anthracyclines) are used, which have been shown to be associated with the 11q23 rearrangement (KMT2A, previously MLL) [24, 25]. The gene discussed is KMT2A; the disease is acute promyelocytic leukemia.